175 related articles for article (PubMed ID: 15852403)
1. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
[TBL] [Abstract][Full Text] [Related]
2. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
3. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS.
Li W; Brakefield D; Pan Y; Hunter D; Myckatyn TM; Parsadanian A
Exp Neurol; 2007 Feb; 203(2):457-71. PubMed ID: 17034790
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
5. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.
Franz CK; Federici T; Yang J; Backus C; Oh SS; Teng Q; Carlton E; Bishop KM; Gasmi M; Bartus RT; Feldman EL; Boulis NM
Neurobiol Dis; 2009 Mar; 33(3):473-81. PubMed ID: 19135533
[TBL] [Abstract][Full Text] [Related]
6. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
[TBL] [Abstract][Full Text] [Related]
7. Has gene therapy for ALS arrived?
Miller TM; Cleveland DW
Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
[No Abstract] [Full Text] [Related]
8. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.
Nagano I; Ilieva H; Shiote M; Murakami T; Yokoyama M; Shoji M; Abe K
J Neurol Sci; 2005 Aug; 235(1-2):61-8. PubMed ID: 15990113
[TBL] [Abstract][Full Text] [Related]
10. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.
Messi ML; Clark HM; Prevette DM; Oppenheim RW; Delbono O
Exp Neurol; 2007 Sep; 207(1):52-63. PubMed ID: 17597610
[TBL] [Abstract][Full Text] [Related]
11. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.
Corti S; Locatelli F; Papadimitriou D; Del Bo R; Nizzardo M; Nardini M; Donadoni C; Salani S; Fortunato F; Strazzer S; Bresolin N; Comi GP
Brain; 2007 May; 130(Pt 5):1289-305. PubMed ID: 17439986
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS.
Zheng C; Nennesmo I; Fadeel B; Henter JI
Ann Neurol; 2004 Oct; 56(4):564-7. PubMed ID: 15389897
[TBL] [Abstract][Full Text] [Related]
13. Disease progression of human SOD1 (G93A) transgenic ALS model rats.
Matsumoto A; Okada Y; Nakamichi M; Nakamura M; Toyama Y; Sobue G; Nagai M; Aoki M; Itoyama Y; Okano H
J Neurosci Res; 2006 Jan; 83(1):119-33. PubMed ID: 16342121
[TBL] [Abstract][Full Text] [Related]
14. Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA.
Yokota T; Sasaguri H; Saito Y; Yamada H; Unno T; Yamamoto Y; Kubodera T; Anzai M; Mitani T; Mizusawa H
Arch Neurol; 2007 Jan; 64(1):145-6. PubMed ID: 17210827
[No Abstract] [Full Text] [Related]
15. Altered distribution and levels of cathepsinD and cystatins in amyotrophic lateral sclerosis transgenic mice: possible roles in motor neuron survival.
Wootz H; Weber E; Korhonen L; Lindholm D
Neuroscience; 2006 Dec; 143(2):419-30. PubMed ID: 16973300
[TBL] [Abstract][Full Text] [Related]
16. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis.
Petri S; Kiaei M; Damiano M; Hiller A; Wille E; Manfredi G; Calingasan NY; Szeto HH; Beal MF
J Neurochem; 2006 Aug; 98(4):1141-8. PubMed ID: 16895581
[TBL] [Abstract][Full Text] [Related]
17. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
[TBL] [Abstract][Full Text] [Related]
18. Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis.
Garbuzova-Davis S; Willing AE; Milliken M; Saporta S; Zigova T; Cahill DW; Sanberg PR
Exp Neurol; 2002 Apr; 174(2):169-80. PubMed ID: 11922659
[TBL] [Abstract][Full Text] [Related]
19. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.
Tanase K; Teng Q; Krishnaney AA; Liu JK; Garrity-Moses ME; Boulis NM
J Neurosurg Spine; 2004 Jul; 1(1):128-36. PubMed ID: 15291033
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases.
Alisky JM; Davidson BL
Hum Gene Ther; 2000 Nov; 11(17):2315-29. PubMed ID: 11096437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
